ADPT Up 22% in One Month: Is It Outperforming Its Rivals?
Here is how Adaptive Biotechnologies (ADPT) stacks up against its peers in size, valuation, growth and margin.
- ADPT’s operating margin of -59.0% is negative, lower than most peers – trailing UTHR (50.1%).
- ADPT’s revenue growth of 21.6% in the last 12 months is strong, outpacing VRTX, REGN, ALNY, UTHR but lagging MDGL.
- ADPT gained 195.5% in the past year and trades at a PE of -16.3, outperforming its peers.
As a quick background, Adaptive Biotechnologies provides an immune medicine platform with immunosequencing technology for translational research, diagnostics, and drug discovery across life sciences and clinical applications.
| ADPT | VRTX | REGN | ALNY | MDGL | UTHR | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 2.0 | 101.4 | 62.0 | 58.9 | 9.2 | 14.1 |
| Revenue ($ Bil) | 0.2 | 11.4 | 14.2 | 2.3 | 0.5 | 3.1 |
| PE Ratio | -16.3 | 27.9 | 13.9 | -218.5 | -32.7 | 11.3 |
| LTM Revenue Growth | 21.6% | 10.5% | 5.4% | 17.2% | 3422.0% | 17.6% |
| LTM Operating Margin | -59.0% | -1.7% | 27.0% | -4.9% | -60.1% | 50.1% |
| LTM FCF Margin | -40.4% | 30.6% | 25.0% | -3.2% | -59.8% | 34.8% |
| 12M Market Return | 195.5% | -17.7% | -50.2% | 63.8% | 66.8% | -10.0% |
Why does this matter? ADPT just went up 22% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell ADPT Stock to see if Adaptive Biotechnologies holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through ADPT Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ADPT | 21.6% | 5.1% | -8.1% | 20.1% |
| VRTX | 10.5% | 11.7% | 10.5% | 17.9% |
| REGN | 5.4% | 8.3% | 7.8% | -24.3% |
| ALNY | 17.2% | 23.0% | 76.2% | 22.9% |
| MDGL | 3422.0% | ∞% | � | � |
| UTHR | 17.6% | 23.6% | 20.2% | 14.9% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ADPT | -59.0% | -86.8% | -118.4% | -108.0% |
| VRTX | -1.7% | -2.1% | 38.3% | 47.6% |
| REGN | 27.0% | 28.1% | 30.9% | 38.9% |
| ALNY | -4.9% | -7.9% | -15.4% | -75.7% |
| MDGL | -60.1% | -276.4% | � | � |
| UTHR | 50.1% | 50.3% | 50.9% | 50.6% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ADPT | -16.3 | -5.5 | -3.1 | -5.4 |
| VRTX | 27.9 | -193.9 | 29.0 | 22.3 |
| REGN | 13.9 | 17.4 | 23.7 | 17.8 |
| ALNY | -218.5 | -108.0 | -54.3 | -25.6 |
| MDGL | -32.7 | -14.1 | -11.6 | -16.8 |
| UTHR | 11.3 | 13.3 | 10.4 | 17.4 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.